Navigation Links
CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
Date:1/30/2008

ORLANDO, Fla., Jan. 30 /PRNewswire/ -- John Wagner, M.D., recognized as a leader in the field of cord blood stem cell transplantation, has joined the team at CORD:USE Cord Blood Bank. Dr. Wagner's extensive experience and knowledge in transplant medicine and stem cell biology will provide a significant contribution to CORD:USE.

"We're honored and fortunate to have him as a member of our distinguished team," says Edward Guindi, M.D., President and CEO of CORD:USE Cord Blood Bank.

Dr. Wagner is internationally recognized as an expert in the field of stem cells and use of unrelated hematopoietic stem cell transplant. He is a professor of Pediatrics and the Director of the Division of Hematology- Oncology and Blood and Marrow Transplantation at the University of Minnesota. He is also the Scientific Director of Clinical Research of the Stem Cell Institute and Director of the Center of Molecular and Cellular Therapeutics.

Dr. Wagner has played a considerable role in the development and expansion of the applications of cord blood stem cells. His investigations on the simultaneous use of two cord blood units for transplantation in adults has made it possible for nearly all patients to benefit from cord blood stem cell transplantation who otherwise would not have been candidates for this therapy.

"Without question, I look forward to working with such a distinguished board of scientific advisors and the impressive team at CORD:USE," says Dr. Wagner. "Cord blood stem cells have already played an extremely important role in the treatment of thousands of patients, and I foresee the uses of cord blood expanding, such as in the field of regenerative medicine and tissue repair. The experience and expertise of the team at CORD:USE will help ensure that CORD:USE remains a leader in the field."

Dr. Wagner joins other highly-respected leaders in the field of cord blood stem cell transplantation at CORD:USE. Dr. Joanne Kurtzberg is the Director of the Pediatric Blood and Marrow Program at Duke University and the Medical Director of the CORD:USE Cord Blood Bank at Duke. She performed the first transplantation using an unrelated donor's stem cells and has since performed over 800 umbilical cord blood transplants.

Dr. Wagner also joins Dr. Hal Broxmeyer, a founder of the field of cord blood stem cell transplantation and widely recognized as one of the foremost experts in the world in cord blood stem cell science. Also on the CORD:USE team is Dr. Alan Levine, who serves as the company's Chief Scientific Officer. Dr. Levine enjoyed a highly successful 25-year career with the National Institutes of Health ("NIH") where he was most recently the Director of the Blood Disease Program of the National Heart, Lung, and Blood Institute of the NIH. In this capacity, Dr. Levine was responsible for initiating the bone marrow and umbilical cord blood research programs at the NIH.

Dr. Levine works closely with CORD:USE team member Dr. Esmail Zanjani, a world-renowned expert in blood stem cell biology who has led the development of the field of in utero stem cell transplantation and gene therapy as a means for curing genetic diseases prior to birth.

About CORD:USE Cord Blood Bank, Inc.

CORD:USE Cord Blood Bank, headquartered in Orlando, Florida, is creating a large, ethnically diverse, high quality inventory of available cord blood stem cell units for the many patients in need of a potentially life-saving transplant. Cord blood stem cells have been used successfully in the treatment of over 70 blood cancers and diseases. CORD:USE Cord Blood Bank has entered into agreements with hospitals across the country to provide mothers the option to donate their babies' cord blood. CORD:USE distributes cord blood units to transplanters, throughout the country and the world, as a critical component in their patients' treatment. CORD:USE lists all of its units on the National Marrow Donor Program's Registry. For more information, please visit our Web site http://www.corduse.com or contact Michael Ernst at 407-667- 4844 or by e-mail at mernst@corduse.com.


'/>"/>
SOURCE CORD:USE Cord Blood Bank, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... President for Public Policy for the National Organization for Rare Disorders (NORD). Dorman ... to ensure their voices are heard throughout the drug regulatory review process. , ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
(Date:2/9/2016)... 2016 DelveInsight,s, "Protein-Tyrosine ... provides in depth insights on the pipeline ... Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Biology Technology:
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):